The Middle East & Africa veterinary/animal vaccines market is poised to reach USD 0.56 Billion by 2027 from USD 0.43 Billion in 2022, at a CAGR of 5.48% from 2022 to 2027. Veterinary Vaccines are essential and, at times, crucial tools for preventing or controlling the given animal disease. Still, they require complementary actions like enabling legislation, investment for diagnostic, early response, public communication, etc.
The growing demand for livestock products (fuelled by population growth, increased urbanization, and higher purchasing power of individuals in developing or middle-income countries) coupled with the necessity of complying with the standards of trade agreements, mean that governments in the Middle-East & Africa region must improve animal health in their countries.
The veterinary vaccine market has shown significant growth in recent years, attributed to increasing incidences of animal pandemics in the region. Contagious bovine pleuropneumonia is endemic in numerous areas of Africa and is suspected to occur occasionally in the Middle East. Rift Valley fever (RVF) is an insect-borne, multi-species zoonotic viral disease of livestock that has been exclusively confined to the African continent. Still, it began spreading to the Middle East in the past decade. It marks the estimation of further growth in the market in terms of livestock vaccine sales. However, International and regional collaboration have proven successful in the progressive control of these pandemics, e.g., the Pan American Foot-and-Mouth Disease Centre in South America and the European Union FMD Commission, which this region lacks. Therefore, it makes the adoption of regulations that much harder in the area.
Rising maintenance costs for the storage of vaccines and increasing adoption of a vegetarian diet in major economies due to the increased risk of obesity and other chronic diseases are key restraints of this market.
This research report on the Middle East and Africa veterinary vaccines market has been segmented and sub-segmented into the following categories:
The MEA animal vaccines market is anticipated to register a considerable share in the global market during the forecast period due to the rising adoption of pets, increasing product availability, and technologically advanced vaccines. Also, the outbreak of livestock diseases is influencing the market growth. The animal vaccine industry in MEA has seen a shift in trend from live attenuated vaccines to DNA vaccines, and recombinant vaccination solutions have been quickly adopted. Many industries have come to a standstill as a result of the present COVID-19 epidemic. Most import-export firms worldwide are experiencing significant losses in income creation and market position in their respective countries. But this, too, shall pass. Companies are anticipated to benefit from several government programs.
The South Africa animal vaccines market is expected to account for a significant share in the MEA animal vaccines market during the forecast period due to the increase in the incidence of zoonotic diseases, growing companion animals, and Improving quality and effectiveness in the production of poultry products. Also, the growing demand for animal-derived food products is increasing the market revenue.
On the other hand, developing countries such as Saudi Arabia and UAE will witness a moderate share in the animal vaccine market. The market growth is anticipated to be fuelled by the initiatives taken by the government agencies and animal associations and increasing investments in animal healthcare.
KEY MARKET PLAYERS:
Companies playing a prominent role in the MEA veterinary vaccines market profiled in this report are Bayer HealthCare AG, Bioniche Animal Health Canada, Sanofi Animal Health Inc., Biogenesis Bago SA, Heska Corporation, Indian Immunologicals Ltd., Boehringer Ingelheim GmbH, Zoetis, Novartis Animal Health Inc., Merck & Co Inc., and Protein Sciences.
Access the study in MULTIPLE FORMATS
Purchase options starting from $ 2000
Call us on: +1 888 702 9696 (U.S Toll Free)
Write to us: email@example.com